The natural history of cancers can be understood through the lens of evolution given that the
driving forces of cancer development are mutation and selection of fitter clones. Cancer …

Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …

Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …

Breast cancer is a heterogeneous disease and differs greatly among different patients
(intertumor heterogeneity) and even within each individual tumor (intratumor heterogeneity) …

Cancer is one of the greatest threats facing our society, being the second leading cause of
death globally. Currents strategies for cancer diagnosis consist of the extraction of a solid …

The human epidermal growth factor receptor 2 (HER2) is a well-known negative prognostic
factor in breast cancer and a target of the monoclonal antibody trastuzumab as well as of …

Ductal carcinoma in situ (DCIS) is an early-stage breast cancer that infrequently progresses
to invasive ductal carcinoma (IDC). Genomic evolution has been difficult to delineate during …

Cancers have the ability to develop resistance to traditional therapies, and the increasing
prevalence of these drug resistant cancers necessitates further research and treatment …

Reconstructing lineage relationships between cells within a tissue or organism is a long-
standing aim in biology. Traditionally, lineage tracing has been achieved through the …